Stock Analysis·← Pickers

NGEN

NervGen Pharma Corp. Common stock

NervGen Pharma Corp. Common stock (NGEN) is currently in a range/mixed trend. RSI is at 32.7, with 0/3 trend checks passing.

Price
$1.69
2026-07-16
Trend score
0/3
Range / Mixed
RSI (14)
32.7
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

NGEN with MA50 and MA200

5.974.903.832.761.6912/1002/0403/3005/2007/15
NGEN2025-12-102026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$2.46-31.22% vs price
MA200
Distance unavailable
RSI (14)
32.7Neutral zone
MACD Signal
MixedMACD near signal line
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for NGEN

NervGen Pharma Corp. Common stock (NGEN) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $1.69, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 31.2%.

Momentum and stretch context

NGEN currently has an RSI reading of 32.7, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.

What traders may watch next

This page is designed to help you quickly understand what the NGEN chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About NervGen Pharma Corp. Common stock

NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.

Sector
Healthcare
Industry
Biotechnology
CEO
Adam H. Rogers
Employees
7
Market cap
$138.9M
Beta
0.69
52-week range
$1.68 – $6.30
Dividend
No
Exchange
NASDAQ
Country
CA
IPO date
8 Feb 2021
ISIN
CA64082X2032
CUSIP
64082X203
Company profile data from Financial Modeling Prep. NGEN listed on NASDAQ.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about NGEN

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.

NGEN Stock Analysis: Range/Mixed trend, RSI 33 | MyStockHarbor